HUTCHMED Presents P-II (SAVANNAH) Trial Results of Savolitinib + Tagrisso (osimertinib) for EGFR-Mutated NSCLC at WCLC 2022
Shots:
- The P-II (SAVANNAH) trial evaluates savolitinib + AstraZeneca’s Tagrisso in 294 EGFR-mutated NSCLC patients with MET-driven tumors, following disease progression on treatment with Tagrisso
- At the data cut-off date of Aug 2022, the results from an analysis of 193 efficacy evaluable patients who received savolitinib (300mg, qd) + TAGRISSO (80mg, qd) showed improved response rates with increasing levels of MET aberration, ORR (32%), m-DoR (8.3mos.), m-PFS (5.3mos.). The results were consistent with the prior results from the (TATTON) exploratory study
- Patients who exhibited higher cut-off MET abnormality levels, ORR was 49%, m-DoR (9.3mos.) & m-PFS (7.1mos.). The safety profile was consistent with the known profiles of the combination & each treatment alone
Ref: HUTCHMED | Image: HUTCHMED
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
